Counting my change
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
PositiveID Corporation (NASDAQ: PSID) announced that it has reported financial results for the quarter ended March 31, 2010, its first full quarter of operations since its acquisition of Steel Vault Corporation in November 2009 and the resulting name change to PositiveID. The Company reported revenues of $673,000 for the first quarter of 2010, compared to revenues of $8,000 for the first quarter of 2009.
As of May 10, 2010 the Company has cash of $5.9 million, inclusive of the first tranche (gross proceeds of $2.3 million) of the recently announced $4.2 million non-convertible preferred stock purchase agreement with Socius Technology Capital Group. PositiveID has no debt. Scott R. Silverman, Chairman and CEO of PositiveID, said, "As we continue to move ahead with the development of our HealthID product portfolio, we believe our strategic direction is well defined and the time has come to initiate quarterly results press releases. We have a strong balance sheet and expect to continue to build our HealthID business, focusing on rapid and unique medical testing devices for both humans and animals."
Must See..BIEL FDA Status Video
http://www.joenoelstocks.com/uncategorized/joe-noel-biel-ceo-whelan-discusses-fda-clearance-status-and-new-products/
Strategy bets on end to Pozen's free-fall
commentary by: David Russell
Pozen has been collapsing since the end of April, and now one trader is calling a bottom.
optionMONSTER's tracking systems detected the sale of more than 4,400 May 7.50 puts on the drug developer, most of which priced for $0.25 to $0.30. The trade reflects a belief the shares will remain above the strike through expiration, and will benefit from the increased pace of time decay that will occur as May 21 approaches.
POZN ChartPOZN rose 0.86 percent to $8.24 in afternoon trading. The stock surged to an 18-month high after reporting better-than-expected results on April 29 but then fell in every session until today. The decline came despite regulators approving its Vimovo pain drug on April 30.
Today's put sale comes after POZN rebounded from the same $8 level that served as resistance last year. Some chart watchers may interpret the price action as evidence of support and be willing to write put protection below that level.
Given the premium earned, the shares would have to fall all the way to $7.25 before they lose money.
The transaction also appeared after implied volatility on the stock plunged from over 175 percent to about 70 percent in the wake of earnings and the Vimovo news. The put seller probably expects volatility to remain subdued through expiration, which will help keep down the value of the contracts sold short.
Great News Just In...Just talked to the CEO Paul Wilkinson,Production has been confirmed for May 18,19th.This roll out will include the Whole Foods order and misc. consumer orders. Website internet credit card acceptance should happen this week.I asked about the Whole food order and he said the products have already been tested by Whole Foods and the Atlanta region is the hardest to get into,making the rest of the US easier once launched.The master broker is working aggressively in getting other large chains on board.
Stock Alert for Positron Corp. Issued by MicroStockProfit
globenewswire
Press Release Source: MicroStockProfit.com On Monday May 10, 2010, 6:50 am
DALLAS, May 10, 2010 (GLOBE NEWSWIRE) -- MicroStockProfit.com announces an investment report featuring Positron Corp. (OTCBB:POSC - News). The report includes financial, comparative and investment analyses, and industry information you need to know to make an educated investment decision.
The full report is available at: www.microstockprofit.com/ads/POSC
Positron Corp. (POSC) is a molecular imaging company focused on Nuclear Cardiology. Positron utilizes its product line to provide solutions to the Nuclear Medicine community ranging from imaging to radiopharmaceutical distribution. Positron products include the Attrius, a positron emission tomography (PET) imaging device; the Pulse, a single photon emission computerized tomography (SPECT) imaging device; the Nuclear Pharm-Assist, an automated radiopharmaceutical distribution device; and the Tech-Assist, a radiopharmaceutical injection shield. Positron's SPECT and PET cardiac molecular imaging devices are installed in more than 175 hospitals and physician offices worldwide. Positron offers a cardiac reasonably priced PET system in North America. Positron, through its China based joint venture, Neusoft Positron Medical Systems, has upgraded its PET imaging system.
Message Board Search for POSC: http://www.boardcentral.com/boards/POSC
In the report, the analyst notes:
"The Company generated revenues of $1,446,000 and $2,126,000 for the years ended December 31, 2009, and 2008, respectively. Revenue from service contracts totaled $827,000 and $1,150,000 for the years ended December 31, 2009, and 2008, respectively. The decrease in service is due to in large part to the continuous decline of sales of both PET systems and PulseCDC gamma cameras. Additionally, some existing service contracts were either terminated or moved to time and materials billing, which resulted in lower revenue.
"The Company's Nuclear Pharm-Assist(R), an automated radiopharmaceutical dose dispensing device, aims to greatly transform the way healthcare providers serve patients seeking care for numerous cardiac and cancer diseases. The innovative device has been attracting significant new partners by streamlining the production, dispensing and delivery of radiopharmaceuticals."
To read the entire report visit: www.microstockprofit.com/ads/POSC
See what investors are saying about POSC at penny stock forum
MicroStockProfit.com is a small-cap research and investment commentary provider. MicroStockProfit.com strives to provide a balanced view of many promising small-cap companies that would otherwise fall under the radar of the typical Wall Street investor. We provide investors with an excellent first step in their research and due diligence by providing daily trading ideas, and consolidating the public information available on them. For more information on MicroStockProfit please visit: http://www.microstockprofit.com
MicroStockProfit.com Disclosure
MicroStockProfit.com is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell any securities. MicroStockProfit.com is a Web site wholly owned by BlueWave Advisors, LLC. Neither MicroStockProfit.com nor its affiliates have a beneficial interest in the mentioned company; nor have they received compensation of any kind for any of the companies listed in this communication. Please read our report and visit our Web site, MicroStockProfit.com, for complete risks and disclosures.
Contact:
MicroStockProfit.com
Brian Johnson
1-888-307-2850
info@microstockprofit.com
Happy Mothers Day!!!
Yes,this normal with substantial news.
News for 'POSC' - (Positron Showcased at NASDAQ Marketsite)
INDIANAPOLIS, May 06, 2010 (BUSINESS WIRE) -- Positron Corporation (OTCBB:POSC)
(the "Company") a molecular imaging solutions company focused on Nuclear
Cardiology, announced the highlights from the Company's presentation before
NASDAQ on May 5, 2010.
The Management of Positron Corporation introduced the Company at the NASDAQ
Marketsite. This forum is of great value to Positron since it provides broad
exposure and access to a far reaching investment community.
The Company set out to explain the foundation of its business, the confirmation
of a strategic partnership and potential revenue. Management discussed most all
aspects of the Company's plans which it was at liberty to disclose. A transcript
of the presentation will be filed with the Securities and Exchange Commission on
a Form 8-K immediately when it becomes available in coming days.
Positron representatives did confirm an agreement with an industry leading
strategic partner that will give the Company the ability to greatly expand the
Company's revenue stream and our position in the molecular imaging market by
offering imaging systems and radiopharmaceutical distribution. Patrick Rooney,
Positron Corporation's CEO states, "We would have liked to introduce a certain
synergistic business partner as was stated in the press; however it was the
recommendation of both companies to not disclose further details due to a
potential expansion relationship and certain strategic competitive advantages.
We anticipate additional information will be disclosed in the near future."
Positron also gave guidance as to its target revenue. Based on the Company's
research and unique positioning in the marketplace, Positron projects
significant sales growth quarter over quarter, year over year. Positron projects
that in the next 5 years the nuclear cardiology market will approach $1.5
Billion in revenue annually. The projections reflected sales from Positron's PET
device and radiopharmaceutical devices and services. Positron may potentially
achieve greater revenue as it expands into new markets with broader indications
that we expect will be fully supported by Medicare and private payers.
About Positron: Positron founded in 1983, is a molecular imaging company focused
on Nuclear Cardiology. Positron utilizes its proprietary product line to provide
unique solutions to the Nuclear Medicine community ranging from imaging systems
to radiopharmaceutical distribution. Positron products include: the Attrius(TM),
a PET imaging device; the Pulse(R), a SPECT imaging device; the Nuclear
Pharm-Assist(R), an automated radiopharmaceutical distribution device; and the
Tech-Assist(TM), a radiopharmaceutical injection shield. Positron is
headquartered in Indianapolis, Indiana. More information about Positron is
available at www.positron.com.
Forward Looking Statements: Statements in this document contain certain
forward-looking statements within the meaning of Section 27A of the Securities
Act of 1933 and the Securities Exchange Act of 1934, as amended. These
statements are based on many assumptions and estimates and are not guarantees of
future performance and may involve known and unknown risks, uncertainties and
other factors which may cause the actual results, performance or achievements of
Positron Corporation to be materially different from future results, performance
or achievements expressed or implied by such forward-looking statements. Our
actual results may differ materially from the results anticipated in these
forward-looking statements due to a variety of factors, including, without
limitation those set forth as "Risk Factors" in our filings with the Securities
and Exchange Commission.
For further information please contact Positron Corporation at (317) 576-0183.
SOURCE: Positron Corporation
CONTACT:
Positron Corporation
Patrick Rooney
(317) 576-0183
CYTX May 2010 Shareholder Letter
http://ir.cytoritx.com/InvestorRelations/releasedetail.cfm?ReleaseID=467040
CYTX May 2010 Shareholder Letter
http://ir.cytoritx.com/InvestorRelations/releasedetail.cfm?ReleaseID=467040
I ordered 3 of the vegi dips and one spread.
Absolutely serious. I am just waiting for a call on payment and confirmation of order.What I am excited about is production starting next week and they will be automated to accept payments on the web very soon.
Lifeline Biotechnologies Comments on DTC Notice Resulting from SEC Administrative Action Against Leeb Brokerage Services, Inc.
businesswire
Press Release Source: Lifeline Biotechnologies, Inc. On Wednesday May 5, 2010, 4:31 pm
RENO, Nev.--(BUSINESS WIRE)--Lifeline Biotechnologies, Inc. (Pink Sheets: LLBO - News) has learned that the U.S. Securities and Exchange Commission has filed an administrative action against employees of New York brokerage Leeb Brokerage Services Inc. (Leeb) for facilitating illegal penny stock sales. As a consequence of the SEC action, Depository Trust Company (DTC) has suspended all services, except custody services, for Lifeline Biotechnologies shares.
Lifeline is one of a number of companies whose shares were allegedly utilized in the activities of the brokerage firm Leeb. According to an SEC administrative action in 2006, Leeb conducted possible illegal trading for clients holding shares of Lifeline and other companies. Lifeline’s CEO, Jim Holmes, stated, “Lifeline has no knowledge of, or association with, Leeb or any of its affiliates or employees, and was in no way a party to the actions of the broker, its employees or affiliates. We are in contact with DTC to clear Lifeline’s name of the matter and to remove the suspension of services on the shares of Lifeline as soon as possible. We will follow up with news on the state of affairs as soon as it is known.”
To learn more about this matter and read the case of administrative action, please see the following links:
DTC Notice: http://www.dtcc.com/downloads/legal/imp_notices/2010/dtc/ope/6676-10.pdf
SEC Administrative Action: http://www.sec.gov/litigation/admin/2010/33-9121.pdf
Safe Harbor: This release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 27E of the Securities Act of 1934. Statements contained in this release that are not historical facts may be deemed to be forward-looking statements. Investors are cautioned that forward-looking statements are inherently uncertain. Actual performance and results may differ materially from that projected or suggested herein due to certain risks and uncertainties including, without limitation, the ability to obtain financing, successful development of the Company's product or market acceptance of the product and regulatory and shareholder approval for anticipated actions.
Contact:
Lifeline Biotechnologies, Inc., Reno
Jim Holmes, 775-324-1933
Jholmes@lbti.com
www.lbti.com
Just placed my first order!
Good news , I talked to corporate and they are taking individual orders now. You need to place the order on the internet and they will call you back,then will e-mail you a paypal form to pay. They are going into production next week!!! They will also be automating the payment system on the web very soon to accept credit cards!! This is fantastic news...let the games begin.
Added Pozn also! This is a solid stock and will rise near -term
This is excellent news,this company is going to take off soon. Remember, Duane Reed stores were bought by Walgreen's. If they get in the Walgreen's chain watch out.
Clear Skies Completes First 2010 Project for $680K
First of Several Successful Q1 Projects
CEO comments on anticipated momentum
prnewswire
Press Release Source: Clear Skies Solar, Inc. On Wednesday May 5, 2010, 6:00 am EDT
MINEOLA, N.Y., May 5 /PRNewswire-FirstCall/ -- Clear Skies Solar, Inc. (CSS) (OTC Bulletin Board:CSKH.ob - News), a full-service renewable energy provider to commercial, industrial, and agricultural clients today announced the completion of the $680,000 project on the old Linens & Things building located within the Livingston Shopping Plaza in New Jersey. The completed system is a 185 kW rooftop ballasted design with Suntech 270 panels and 2-PV Power inverters.
(Logo: http://www.newscom.com/cgi-bin/prnh/20090306/CSSLOGO )
"We started this project on March 4, 2010 and completed installation only eight days later, which was ahead of schedule as well as being on budget," commented Ezra Green, CEO of Clear Skies Solar. "We believe the successful completion of this project continues to show that our Company can successfully operate under a variety of conditions bringing in projects with high quality, with budget constraints and ahead of schedule. While our thorough pre-project planning and analysis adds some lead time to the execution of our projects, once full viability and adherence to all electrical, building and safety codes are established, implementation typically goes much smoother with a higher level of overall client satisfaction."
Mr. Green, continued, "With our first of several systems of 2010 now complete and operating at peak efficiency, we are proud to announce that as stated in previous communications with our investors, CSS is successfully emerging from the market downturn seen during 2009. Our world-class operations team has outperformed on every project over the past few years and is focused on delivering the same high quality at an accelerated rate over the near term. Our project momentum is building at the healthy anticipated pace, as we have outlined. We look forward to 2010 being a great year for both our Company and for our shareholders."
About Clear Skies Solar, Inc.
Clear Skies Solar, Inc. (CSS) through its wholly-owned subsidiary provides full-service renewable energy solutions to commercial, industrial, and agricultural clients across the country. CSS was incorporated in 2003 and launched formal operations in 2005. During that time period, CSS developed its proprietary systems, obtained licenses and certifications, and acquired technologies that could maximize the impact of its construction expertise in the renewable energy sector. CSS has become one of the premier solar electric installation companies in the country. For more information about CSS please visit http://www.clearskiessolar.com.
Remember...good stocks will always recover,POZN definitely will.
Insider Buying on NEOP
SOURCE: Form 4
ISSUER: NEOPROBE CORP
SYMBOL: NEOP
FILER: BUPP DAVID C
TITLE: Chief Executive Officer
DATE TRANSACTION SHARES PRICE VALUE
5/3/10 Purchase 30,000 $1.81 $54,195
OWNERSHIP: 920,649 (Direct) 285,003 (Indirect)
The Form 4 is filed with the Securities and Exchange Commission by insiders
to report transactions in their companies' shares. Open market purchases
and sales must be reported within two business days of the transaction.
Insider Data Source: The Washington Service
(info@washingtonservice.com or 301-913-5100)
Insider Buying on NEOP
SOURCE: Form 4
ISSUER: NEOPROBE CORP
SYMBOL: NEOP
FILER: BUPP DAVID C
TITLE: Chief Executive Officer
DATE TRANSACTION SHARES PRICE VALUE
5/3/10 Purchase 30,000 $1.81 $54,195
OWNERSHIP: 920,649 (Direct) 285,003 (Indirect)
The Form 4 is filed with the Securities and Exchange Commission by insiders
to report transactions in their companies' shares. Open market purchases
and sales must be reported within two business days of the transaction.
Insider Data Source: The Washington Service
(info@washingtonservice.com or 301-913-5100)
POZN on the move
PSID - News..Revolutionary Glucose Breath Test Attracting Potential Partners
marketwire
Press Release Source: BiomedReports On Tuesday May 4, 2010, 3:10 pm
LOS ANGELES, CA--(Marketwire - 05/04/10) - PositiveID Corporation (NASDAQ:PSID - News) is developing the non-invasive Easy Check breath glucose analysis system and sources are telling BioMedReports that a bigger company or two have taken an interest in partnering with them for a piece of the huge diabetic market that the test would open up.
As reported earlier, this unique, non-invasive glucose detection system measures the levels of acetone in a diabetic patient's exhaled breath.
It combines a proprietary chemical mixture with exhaled breath, which creates a new molecular compound that can be measured with the Company's patent-pending technology.
Industry sources say a significant partnership may be very close to completion and public announcement. Such news would not only help validate the technology, but would also likely send PSID's tightly floated shares upward.
In the U.S. alone, 23.6 million people (7.8% of the total population) have diabetes. The PSID device could eliminate a patient's need to prick his or her finger multiple times per day to get a blood sugar reading.
Trade alert report with more details is available at BioMedReports.Com
http://biomedreports.com/articles/most-popular/38822-postive-news-coming-for-glucose-breath-test.html
Biotech investors interested in accessing the news portal's database of clinical trials and upcoming FDA decisions can access that information here:
http://biomedreports.com/fda-calendar/fda-calendar.html
About BioMedReports.Com
BioMedReports.com is a news portal covering the biomedical news and financial sector. BioMedReports is not paid or compensated to report news and developments about publicly traded companies.
For more biomedical sector and investment news go to http://BioMedReports.com
Contact:
Media Contact:
Mary Davila
Assistant Editor
BioMedReports.Com
e-mail: Email Contact
Tel: +1 323 472 4480
Fax: +1 888 210 3556
Bio Stock Tip of the Day....When you are on Prozac,everyday is a happy one.
KngmAZ,you are 300% correct! You always take care of the big boys first
Data from Transdel Pharmaceuticals' Phase 3 Study to be Presented at 13th World Congress on Pain
prnewswire
Press Release Source: Transdel Pharmaceuticals, Inc. On Tuesday May 4, 2010, 8:00 am
LA JOLLA, Calif., May 4 /PRNewswire-FirstCall/ -- Transdel Pharmaceuticals, Inc. (OTC Bulletin Board:TDLP.ob - News), a specialty pharmaceutical company focused on developing topically administered products using its proprietary transdermal delivery platform, today announced that its abstract entitled "Efficacy And Safety Of Ketoprofen 10% Cream In The Treatment Of Pain Associated With Acute Soft Tissue Injuries (Phase 3 Study TDLP-110-001)" was accepted for presentation at the 13th World Congress on Pain to be held August 29 to September 2, 2010 in Montreal, Canada. The poster is to be presented by lead author Dr. Evan Ekman, President of Southern Orthopaedic Sports Medicine in Columbia, SC.
"The upcoming presentation of our data at the world's premier congress devoted to research and treatment of pain is a significant event for our company," said Transdel's Chief Medical Officer, Dr. Joachim Schupp. "We look forward to sharing the full Phase 3 clinical data as it will provide additional insight into the efficacy and safety of Ketotransdel®."
The World Congress on Pain is organized every two years and attracts thousands of the world's leading experts on pain to share their thoughts, research and findings on this critical topic.
About Transdel Pharmaceuticals, Inc.
Transdel Pharmaceuticals, Inc. (OTCBB:TDLP.ob - News) is a specialty pharmaceutical company developing non-invasive, topically delivered products. The Company's innovative-patented Transdel™ cream formulation technology is designed to facilitate the effective penetration of a variety of products through the tough skin barrier. Ketotransdel®, the Company's lead pain product, utilizes the Transdel technology to deliver the active drug, ketoprofen, a non-steroidal anti-inflammatory drug through the skin directly into the underlying tissues where the drug exerts its well-known anti-inflammatory and analgesic effects. The Company intends to leverage its Transdel™ platform technology to expand and create a portfolio of topical products for a variety of indications. The Company is actively pursuing partnerships with companies to expand its product portfolio for pharmaceutical and cosmetic/cosmeceutical products. For more information, please visit http://www.transdelpharma.com.
Forward-Looking Statements
The Company cautions you that the statements included in this press release that are not a description of historical facts are forward-looking statements. These include statements regarding: the Company's interpretation of the results of its Phase 3 clinical trial for Ketotransdel®; whether the results from the clinical trial, along with any other clinical trials that may be required by the FDA, will be sufficient to support a 505(b)2 New Drug Approval (NDA) submission; the potential indications for use for Ketotransdel®; the market opportunity for the Company's products; and the Company's ability to complete additional development activities for products utilizing its proprietary transdermal delivery platform. Actual results may differ materially from those set forth in this press release due to the risks and uncertainties inherent in the Company's business, including, without limitation: the outcome of the final analyses of the data from the Phase 3 clinical trial may vary from the Company's initial conclusions; the FDA may not agree with the Company's interpretation of such results or may challenge the adequacy of the Company's clinical trial design or the execution of the clinical trial; the FDA may continue to require the Company to complete additional clinical trials for Ketotransdel® before the Company can submit a 505(b)2 NDA application; the results of any future clinical trials may not be favorable and the Company may never receive regulatory approval for Ketotransdel®; the third parties upon whom the Company relies to conduct its clinical trials may not perform as expected; technological changes or competitive products or pricing may prevent the Company from successfully commercializing its products; and the Company's current need to raise additional funding to complete its product development plans. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company's filings with the Securities and Exchange Commission, including its Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q filed with the SEC. Such documents may be read free of charge on the SEC's web site at www.sec.gov. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement and the Company undertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof. This caution is made under the safe harbor provisions of Section 21E of the Private Securities Litigation Reform Act of 1995.
Data from Transdel Pharmaceuticals' Phase 3 Study to be Presented at 13th World Congress on Pain
prnewswire
Press Release Source: Transdel Pharmaceuticals, Inc. On Tuesday May 4, 2010, 8:00 am
LA JOLLA, Calif., May 4 /PRNewswire-FirstCall/ -- Transdel Pharmaceuticals, Inc. (OTC Bulletin Board:TDLP.ob - News), a specialty pharmaceutical company focused on developing topically administered products using its proprietary transdermal delivery platform, today announced that its abstract entitled "Efficacy And Safety Of Ketoprofen 10% Cream In The Treatment Of Pain Associated With Acute Soft Tissue Injuries (Phase 3 Study TDLP-110-001)" was accepted for presentation at the 13th World Congress on Pain to be held August 29 to September 2, 2010 in Montreal, Canada. The poster is to be presented by lead author Dr. Evan Ekman, President of Southern Orthopaedic Sports Medicine in Columbia, SC.
"The upcoming presentation of our data at the world's premier congress devoted to research and treatment of pain is a significant event for our company," said Transdel's Chief Medical Officer, Dr. Joachim Schupp. "We look forward to sharing the full Phase 3 clinical data as it will provide additional insight into the efficacy and safety of Ketotransdel®."
The World Congress on Pain is organized every two years and attracts thousands of the world's leading experts on pain to share their thoughts, research and findings on this critical topic.
About Transdel Pharmaceuticals, Inc.
Transdel Pharmaceuticals, Inc. (OTCBB:TDLP.ob - News) is a specialty pharmaceutical company developing non-invasive, topically delivered products. The Company's innovative-patented Transdel™ cream formulation technology is designed to facilitate the effective penetration of a variety of products through the tough skin barrier. Ketotransdel®, the Company's lead pain product, utilizes the Transdel technology to deliver the active drug, ketoprofen, a non-steroidal anti-inflammatory drug through the skin directly into the underlying tissues where the drug exerts its well-known anti-inflammatory and analgesic effects. The Company intends to leverage its Transdel™ platform technology to expand and create a portfolio of topical products for a variety of indications. The Company is actively pursuing partnerships with companies to expand its product portfolio for pharmaceutical and cosmetic/cosmeceutical products. For more information, please visit http://www.transdelpharma.com.
Forward-Looking Statements
The Company cautions you that the statements included in this press release that are not a description of historical facts are forward-looking statements. These include statements regarding: the Company's interpretation of the results of its Phase 3 clinical trial for Ketotransdel®; whether the results from the clinical trial, along with any other clinical trials that may be required by the FDA, will be sufficient to support a 505(b)2 New Drug Approval (NDA) submission; the potential indications for use for Ketotransdel®; the market opportunity for the Company's products; and the Company's ability to complete additional development activities for products utilizing its proprietary transdermal delivery platform. Actual results may differ materially from those set forth in this press release due to the risks and uncertainties inherent in the Company's business, including, without limitation: the outcome of the final analyses of the data from the Phase 3 clinical trial may vary from the Company's initial conclusions; the FDA may not agree with the Company's interpretation of such results or may challenge the adequacy of the Company's clinical trial design or the execution of the clinical trial; the FDA may continue to require the Company to complete additional clinical trials for Ketotransdel® before the Company can submit a 505(b)2 NDA application; the results of any future clinical trials may not be favorable and the Company may never receive regulatory approval for Ketotransdel®; the third parties upon whom the Company relies to conduct its clinical trials may not perform as expected; technological changes or competitive products or pricing may prevent the Company from successfully commercializing its products; and the Company's current need to raise additional funding to complete its product development plans. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company's filings with the Securities and Exchange Commission, including its Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q filed with the SEC. Such documents may be read free of charge on the SEC's web site at www.sec.gov. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement and the Company undertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof. This caution is made under the safe harbor provisions of Section 21E of the Private Securities Litigation Reform Act of 1995.
Updated: Positron Press Conference Set For Tomorrow
Written by Staff and Wire Reports
Tuesday, 04 May 2010 00:00
Just a reminder that the anticipated press conference for Positron Corporation, (OTCBB:POSC) will take place on Wednesday afternoon. As is the case with these forward looking news conferences, shares will likely trade higher on Tuesday and Wednesday morning (in anticipation of the press conference).
Our readers were warned that these types of events also attract day traders whose "sell on news" mentality takes hold of the stock.
We are not implying that this will be the case with POSC, but we have seen it happen time and again and would like those of you who have been following news coverage closely to be aware of the risk of a "buy on rumor, sell on news" event taking place here.
Positron's CEO Believes Impact of New Technology and Partnerships Will Make Company Significantly More Profitable Than Ever
Positron CEO: "It will be evident that we are set to become the leaders in the Cardiac PET market"
Positron Chairman confirms talks; Partnership or Buy-Out News May Follow
If such a sell-off occurs, it may provide investors with a great opportunity to buy back into a company whose immediate future looks very bright- especially if the news is as positive as we've been following and confirming via company press releases and CEO interviews.
POSC's CEO will discuss new initiatives and partnerships and recent highlights including their Frost & Sullivan 2010 North American New Product Innovation Award for their Attrius PET Scanner.
When: May 5, 2010, 1:00 pm EDT
Where: NASDAQ MarketSite, 4 Times Square, New York, NY.
Updated: Positron Press Conference Set For Tomorrow
Written by Staff and Wire Reports
Tuesday, 04 May 2010 00:00
Just a reminder that the anticipated press conference for Positron Corporation, (OTCBB:POSC) will take place on Wednesday afternoon. As is the case with these forward looking news conferences, shares will likely trade higher on Tuesday and Wednesday morning (in anticipation of the press conference).
Our readers were warned that these types of events also attract day traders whose "sell on news" mentality takes hold of the stock.
We are not implying that this will be the case with POSC, but we have seen it happen time and again and would like those of you who have been following news coverage closely to be aware of the risk of a "buy on rumor, sell on news" event taking place here.
Positron's CEO Believes Impact of New Technology and Partnerships Will Make Company Significantly More Profitable Than Ever
Positron CEO: "It will be evident that we are set to become the leaders in the Cardiac PET market"
Positron Chairman confirms talks; Partnership or Buy-Out News May Follow
If such a sell-off occurs, it may provide investors with a great opportunity to buy back into a company whose immediate future looks very bright- especially if the news is as positive as we've been following and confirming via company press releases and CEO interviews.
POSC's CEO will discuss new initiatives and partnerships and recent highlights including their Frost & Sullivan 2010 North American New Product Innovation Award for their Attrius PET Scanner.
When: May 5, 2010, 1:00 pm EDT
Where: NASDAQ MarketSite, 4 Times Square, New York, NY.
Aethlon Medical Announces Cancer Immunotherapy Study
prnewswire
Press Release Source: Aethlon Medical, Inc. On Tuesday May 4, 2010, 7:00 am
SAN DIEGO, May 4 /PRNewswire-FirstCall/ -- Aethlon Medical, Inc. (OTC Bulletin Board:AEMD.ob - News), the pioneer in developing therapeutic filtration devices to address infectious disease and cancer, announced today that it plans to initiate patient recruitment for a cancer immunotherapy study by year end. The pilot study seeks to demonstrate an improved immune function in cancer patients as a result of the Aethlon Hemopurifier® removing tumor-secreted exosomes from the circulatory system. Exosomes induce T-cell apoptosis (programmed cell death), and block T-cell signaling, proliferation, and cytokine production in cancer patients. The Hemopurifier® is the first-in-class medical device to selectively remove infectious viruses and immunosuppressive proteins from the circulatory system.
(Logo: http://www.newscom.com/cgi-bin/prnh/20090325/LA88762LOGO-b)
"The FDA's landmark approval of Provenge from Dendreon Corp last week has opened the door for immunotherapeutic strategies to address cancer," stated Aethlon Chairman and CEO, Jim Joyce. "In this regard, we are going to expand our clinical programs beyond infectious disease as we believe our Hemopurifier® is the sole treatment strategy to directly inhibit exosomes from destroying immune cells needed to combat cancer," stated Joyce.
On April 29th, Provenge became the first immunotherapy approved in the United States. The drug, which targets to enhance patient immune response will be marketed as a treatment for men with advanced prostate cancer that have grown resistant to standard hormone therapy. Cancer treatments that improve the ability of the immune system to attack cancer have been a hope for decades, as the strategy promises for fewer side effects than chemotherapy and invasive procedures. Analysts believe the approval of Provenge will usher in the establishment of a cancer immunotherapy industry.
Researchers recently discovered that the Aethlon Hemopurifier®, which is being advanced to market as an adjunct therapy to improve Hepatitis-C virus (HCV) treatment outcomes, is effective in capturing particles that suppress the immune system of cancer patients. These particles, known as exosomes, are released by solid tumors, lymphomas, and leukemia. High concentrations of circulating exosomes correlate with reduced T-cell production and tumor progression in cancer patients. The ability to preserve immune cells by inhibiting the immunosuppressive activity of exosomes is an unmet medical need that would likely improve patient responsiveness to chemotherapy and other cancer treatment strategies. Like other human studies initiated by Aethlon, the pilot study will be conducted in India, which provides both a proof-of-concept and early commercialization pathway. Treatment data points that verify improved immune function in Hemopurifier® treated patients will be the basis for Aethlon to pursue clinical programs in the United States and the European Union. Aethlon will disclose the site of the pilot study along with treatment protocols in the coming months.
In the interim, Aethlon has initiated in vitro research studies aimed at determining the capability of the Hemopurifier® to capture immunosuppressive exosomes associated with breast cancer and lymphoma. An in vitro study, under the collaboration of Douglas D. Taylor, Ph.D., Professor of Obstetrics, Gynecology, and Women's Health at the University of Louisville, has been initiated to determine the capability of the Hemopurifier® to capture immunosuppressive exosomes associated with breast cancer. Dr. Taylor previously conducted studies that validated the Hemopurifier® was effective in capturing immunosuppressive exosomes associated with ovarian cancer. An in vitro study, under the collaboration of Andrew Raubitschek, M.D., Chair of the Department of Cancer Immunotherapeutics & Tumor Immunology at the Beckman Research Institute of City of Hope in California, has been initiated to determine the capability of the Hemopurifier® to capture lymphoma related exosomes. Dr. Raubitschek is also Co-leader for the Cancer Immunotherapeutics Program at the Comprehensive Cancer Center and Chief of Radioimmunotherapy and Professor, Radiation Oncology also at the City of Hope.
About Aethlon Medical
Aethlon Medical, Inc. creates diagnostic and therapeutic device solutions for infectious disease and cancer. Our lead product, the Hemopurifier® is the first-in-class medical device to selectively capture circulating viruses and immunosuppressive proteins prior to cell and organ infection. Human studies have documented the ability of our Hemopurifier® to reduce viral load in patients infected with Hepatitis-C virus (HCV) and the Human Immunodeficiency Virus (HIV). Our primary clinical and commercialization focus is to establish the Hemopurifier® as an adjunct therapy to enhance and prolong the benefit of traditional infectious disease drug regimens.
The Hemopurifier® is also a broad-spectrum treatment candidate against drug resistant bioterror and pandemic threats. Third party research institutes have verified the capability of the device to capture Dengue Hemorrhagic Virus, Ebola Hemorrhagic Virus, Lassa Hemorrhagic Virus, West Nile Virus, H5N1 Avian Influenza Virus, 2009 H1N1 Influenza Virus, the reconstructed Spanish Flu of 1918 Virus, and Monkeypox Virus, which serves as a model for human Smallpox infection.
Additional information regarding Aethlon Medical can be accessed online at www.aethlonmedical.com.
Certain of the statements herein may be forward-looking and involve risks and uncertainties. Such forward-looking statements involve assumptions, known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Aethlon Medical, Inc. to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. Such potential risks and uncertainties include, without limitation, the capability of the Hemopurifier® to reduce viral loads and other disease conditions or to identify or treat disease conditions such as cancer, including the ability to capture exosomes and the impact that potential ability may have on disease conditions, the Company's ability to raise capital when needed, the Company's ability to complete the development of its planned products, the ability of the Company to obtain FDA and other regulatory approvals permitting the sale of its products, the Company's ability to manufacture its products either internally or through outside companies and provide its services, the impact of government regulations, patent protection on the Company's proprietary technology, product liability exposure, uncertainty of market acceptance, competition, technological change, and other risk factors. In such instances, actual results could differ materially as a result of a variety of factors, including the risks associated with the effect of changing economic conditions and other risk factors detailed in the Company's Securities and Exchange Commission filings.
Contacts:
James A. Joyce
Chairman, CEO
858.459.7800 x301
jj@aethlonmedical.com
Jim Frakes
SVP – Finance
858.459.7800 x 300
jfrakes@aethlonmedical.com
John P. Salvador
Director of Communications and Investor Relations
858.459.7800 x307
jps@aethlonmedical.com
I hope they are cranking sales orders...I will try calling tomorrow.
SPPI is a great stock and still under-valued. It has numerous products in it's pipeline.
Added SNSS - on a forward looking event..Good entry
Lifeline Biotechnologies Expects FDA Consulting Firm's Report
businesswire
Press Release Source: Lifeline Biotechnologies, Inc. On Monday May 3, 2010, 1:20 pm
RENO, Nev.--(BUSINESS WIRE)--Lifeline Biotechnologies, Inc. (Pink Sheets: LLBO - News) today reported expectations of its FDA consultant’s report by the middle of this month. The anticipation is based on the commitment by Lifeline’s FDA consulting firm.
Jim Holmes, Lifeline's CEO, said, “This past January we retained an FDA consulting firm to review our clinical processes and our software systems in order to ensure compliance with FDA verification and validation requirements. We have been working closely with these consultants, providing the information they have requested. The firm has concluded its study for Lifeline’s regulatory strategy and is preparing their findings in a report to be delivered shortly. This firm was retained to the review the existing product, the clinical trial records, as well as the intended use and marketing claims of our First Warning System™. The overall task of the consulting firm is to define a regulatory strategy for the First Warning System™ to obtain product commercialization.”
Doctor Louis Keith, Lifeline’s Vice President and Medical Director, said, “We are eager to receive the consultant’s report. From this study our expectation is to prepare and submit an application to the FDA for a 510(k) marketing clearance.”
Safe Harbor: This release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 27E of the Securities Act of 1934. Statements contained in this release that are not historical facts may be deemed to be forward-looking statements. Investors are cautioned that forward-looking statements are inherently uncertain. Actual performance and results may differ materially from that projected or suggested herein due to certain risks and uncertainties including, without limitation, the ability to obtain financing, successful development of the Company's product or market acceptance of the product and regulatory and shareholder approval for anticipated actions.
Contact:
Lifeline Biotechnologies, Inc.
Jim Holmes, 775-324-1933
Jholmes@lbti.com
www.lbti.com
ADVENTRX Announces 6-Month Stability Data Results for ANX-530
prnewswire
Press Release Source: ADVENTRX Pharmaceuticals, Inc. On Monday May 3, 2010, 8:30 am
SAN DIEGO, May 3 /PRNewswire-FirstCall/ -- ADVENTRX Pharmaceuticals, Inc. (NYSE Amex: ANX) today announced the results of stability tests performed on samples of ANX-530 (vinorelbine injectable emulsion), or Exelbine™, manufactured at the Company's intended commercial manufacturing site. The 6-month stability data are on track to support the submission of the New Drug Application (NDA) for Exelbine.
"These results are what we expected and what we expect to see from the 12-month data," said Brian M. Culley, Chief Executive Officer of ADVENTRX. "Once we have the 12-month data, we will submit the Exelbine NDA, which we expect will take place in the fourth quarter of this year."
About ADVENTRX Pharmaceuticals
ADVENTRX Pharmaceuticals is a specialty pharmaceutical company whose product candidates are designed to improve the performance of existing cancer treatments by addressing limitations associated principally with their safety and use. More information can be found on the Company's web site at www.adventrx.com.
Forward Looking Statements
ADVENTRX cautions you that statements included in this press release that are not a description of historical facts are forward-looking statements that involve risks and assumptions that, if they materialize or do not prove to be accurate, could cause ADVENTRX's results to differ materially from historical results or those expressed or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to: the risk that future stability testing results are not consistent with prior results or are out-of-specification or otherwise do not support comparability between ADVENTRX's prior and intended commercial manufacturing sites or a commercially-viable expiration dating period; the risk that the FDA does not accept a submitted Exelbine NDA for review, including as a result of identifying clinical or nonclinical reasons for a refusal-to-file or identifying CMC reasons that were not identified in the refusal-to-file of the previously submitted Exelbine NDA; ADVENTRX's dependence on the success of Exelbine, and uncertainty as to whether Exelbine will receive regulatory approval or be commercialized successfully; the risk that the bioequivalence data and other information included in the Exelbine NDA may not adequately support bioequivalence with Navelbine®; the potential that changes made in transferring the manufacturing process for Exelbine may result in a lack of comparability between the commercial product and the material used in the bioequivalence trial, and that the FDA may require ADVENTRX to perform additional nonclinical, bioequivalence or clinical studies; the potential for the FDA to impose other requirements to be completed before or after approval of the Exelbine NDA; the risk that ADVENTRX will pursue development activities at levels or on timelines, or will incur unexpected expenses, that shortens the period through which its operating funds will sustain it; and other risks and uncertainties more fully described in ADVENTRX's press releases and periodic filings with the Securities and Exchange Commission. ADVENTRX's public filings with the Securities and Exchange Commission are available at www.sec.gov.
You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date when made. ADVENTRX does not intend to revise or update any forward-looking statement set forth in this press release to reflect events or circumstances arising after the date on which it was made.
New Independent Data Monitoring Committee Established by Hemispherx to Accelerate Global Drug Development
globenewswire
Press Release Source: Hemispherx Biopharma, Inc. On Monday May 3, 2010, 8:00 am
PHILADELPHIA, May 3, 2010 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE AMEX:HEB) (the "Company") announced today the formation of an Independent Data Monitoring Committee (DMC) which will oversee the Company's various drug development programs. The principal role of an independent DMC is to perform interim analyses of the clinical outcome data and to insure the safety of patients in clinical trials. The DMC also plays a critical role in studies that may use Adaptive Design wherein trial design modifications can be made after patient enrollment has started. Adaptive Design will enable Hemispherx to respond to data collected during the trial which may include dropping a treatment arm, modifying the sample size, etc, to increase statistical probability of reaching the desired therapeutic outcome.
The three members of the DMC are Thomas R. Zimmerman Jr., MD, F.A.A.N., Philip R. Roane, Jr., Ph.D. and Anita F. Das, Ph.D. Dr. Zimmerman will act as chairman. They will be the core members of the DMC and, from time to time, their skills and knowledge may be supplemented by experts who bring knowledge of a given indication, geographic familiarity, etc. to the Committee for particular studies.
Dr. Zimmerman has over 12 years of medical monitoring experience for all phases of clinical trials, including safety reporting and narrative writing for NDA's and is a Clinical Associate Professor of Neurology at Robert Wood Johnson Medical School. Dr. Roane is an Associate Professor and Vice Chairman of the Department of Microbiology at Howard University and has served on numerous scientific review panels for the National Institutes of Health and the Department of Defense. Dr. Das is President and Principal Biostatistician of AxiStat, Inc. She serves on the Data and Safety Monitoring Committee established by the Best Pharmaceuticals for Children Act which seeks to improve pediatric therapeutics.
By having a formal independent DMC, the Company puts in place a cumulative and broad knowledge gained by DMC members over the course of multiple clinical studies in multiple treatment indications thus further accruing to the benefit and safety of patients suffering from serious diseases without adequate present therapies. The Company has in the planning stages a number of studies for Ampligen(R) , an investigational therapeutic, and Alferon N Injection(R), both in the U.S. and abroad, including the recently announced initiative in India with Alferon N Injection(R) for the treatment of seriously ill patients hospitalized with influenza, scheduled to begin in the upcoming monsoon season.
About Hemispherx Biopharma
Hemispherx Biopharma, Inc. is an advanced specialty pharmaceutical company engaged in the clinical development of new drug entities for treatment of seriously debilitating disorders. Hemispherx' flagship products include Alferon N Injection(R) (FDA approved for a category of sexually transmitted diseases) and the experimental therapeutics Ampligen(R) and Alferon LDO. Ampligen(R) represents experimental RNA nucleic acids being developed for globally important debilitating diseases and disorders of the immune system. Hemispherx' platform technology includes agents for potential treatment of various severely debilitating and life threatening diseases. Hemispherx has an extensive number of patents comprising its core intellectual property estate and a fully commercialized product (Alferon N Injection(R)). The Company wholly owns and exclusively operates a GMP certified manufacturing facility in the United States for commercial products. For more information please visit www.hemispherx.net.
Information contained in this news release, other than historical information, should be considered forward-looking and is subject to various risk factors and uncertainties. For instance, the strategies and operations of Hemispherx involve risk of competition, changing market conditions, change in laws and regulations affecting these industries and numerous other factors discussed in this release and in the Company's filings with the Securities and Exchange Commission. Any specifically referenced investigational drugs and associated technologies of the Company (including Ampligen(R) and Alferon(R) LDO) are experimental in nature and as such are not designated safe and effective by a regulatory authority for general use and are legally available only through clinical trials with the referenced disorders. The forward-looking statements represent the Company's judgment as of the date of this release. The Company disclaims, however, any intent or obligation to update these forward-looking statements. Clinical trials for other potential indications of the approved biologic Alferon N Injection(R) do not imply that the product will ever be specifically approved commercially for these other treatment indications. Further, the commencement of clinical trials in June, 2010 by Max Neeman in India is its target date but cannot be guaranteed due to a variety of risk factors outside of the parties control and should be regarded only as a forward looking estimate.
Contact:
Hemispherx Biopharma, Inc.
Dianne Will
518-398-6222
ir@hemispherx.net
Interesting Article for POSC followers.. The U.S. Market for SPECT and PET Radiopharmaceuticals
The Radiopharmaceutical Report Includes:
* Analysis of Current and Future Radiopharmaceutical Markets
* Emerging Markets For New Molecular Imaging Platforms
* Good Growth Prospects for New SPECT and PET Radiopharmaceuticals
* Long-Term Effects of the Technetium Shortage on the SPECT Market
* Good Prospects for New PET Cardiology Products and Rubidium PET
* Big Markets for New PET and SPECT Agents for Alzheimer's and Parkinson's
* Promising New PET Oncology Products with Broad Applications
* Technological Trends and Competitive Challenges
* Market Assessment and Sales Forecasts to 2017
The report has a strong focus on new products and technology and emerging market opportunities. This covers nuclear cardiology with both PET and SPECT, targeted oncology and new molecular imaging platforms for PET. It also analyzes the large emerging markets for imaging Alzheimer's and Parkinson's disease with PET and SPECT. This will broaden the base of nuclear medicine and allow nuclear imaging to compete more effectively in the larger imaging marketplace.
There has been some decline in the number of SPECT myocardial perfusion procedures as well as reduced pricing for Cardiolite and Myoview because of generic sestamibi. The technetium shortage has also added pressure that will continue for the near term. This will encourage more physicians to adopt PET for many cardiology applications as soon as the new perfusion agents are approved. Cardiology PET produces better images and offers higher reimbursement than traditional cardiology SPECT. This is also stimulating the market for rubidium PET. Growth is still expected in cardiology SPECT from specialized products for imaging myocardial infarction and neuronal imbalances in patients that need pacemakers or may be subject to congestive heart failure. These products are in late stage development and will be introduced in the near term.
New molecular imaging and therapeutic modalities are also being developed based on apoptosis, angiogenesis and PLE (Phospho-Lipid Ether) tumor targeting. This includes new oncology products for diagnosing and monitoring cellular response to therapy. These molecular imaging platforms will also have therapeutic applications, increasing their versatility and usefulness. This will aid in developing patient specific dosimetry necessary for optimizing dosage and evaluating patient response to therapy. In the long run, this will encourage more investment from biopharmaceutical companies and venture groups that will enhance future market growth.
SPECT and PET Radiopharmaceuticals: Market Analysis and Future Prospects
U.S. sales of SPECT and PET radiopharmaceuticals reached $1.16 billion in 2009 and are expected to rise to $4.76 billion by 2017. Total SPECT radiopharmaceutical sales were down 11.6% in 2009 primarily due to reductions in pricing of perfusion agents with the introduction of generic sestamibi. SPECT procedure volume was also down due to the technetium shortage. These pressures will continue in 2010, but eventually stabilize. In comparison, PET procedures were flat compared with the previous year, but revenue was down slightly because of price weakness in the FDG market. However, future sales growth will be more in line with procedure growth.
Although PET reimbursement has been under pressure for the past 2 years, there has been some relief recently. New indications have been approved and reimbursement has improved for certain procedures, particularly in cardiology. Investment in new PET agents is increasing in all segments, which bodes well for this market once the new products are introduced.
Continuing improvements in imaging technology in both SPECT and PET are allowing higher resolution and shorter imaging times. Radiopharmaceutical doses are also going down due to increased imaging efficiency. This makes nuclear medicine safer than many other imaging modalities, which are threatened with excessive radiation and patient safety issues.
As new products are introduced, SPECT sales should more than double during the forecast period from $817 million in 2009 to $1,737 million by 2017. PET sales will increase more rapidly from $348 million in 2009 to $3,028 million by 2017, an increase of more than 700%. This will come primarily from new products as well as increases in the volume of FDG procedures. Market growth will also result from higher prices of the new products. This influx will help all segments of nuclear medicine expanding the platform for molecular imaging. One effect is that clinicians will have more options as alternatives to higher risk and more costly invasive procedures. This will stimulate more research and investment, adding strength and stability to newer venture companies as well as those more established in the field.